Nsclc

D3 Bio Unveils Breakthrough First‑Line Results for ELISRASIB at ASCO 2026

D3 Bio’s First‑Line Data Shows Landmark Efficacy of Elisrasib in KRAS G12C‑Positive NSCLC

A Significant Setback: Arcus Biosciences Halts Key Lung Cancer Trial with Gilead

Summit Therapeutics on the Cusp: A Dual-Action Lung Cancer Drug Faces its Moment of Truth

ArriVent BioPharma: Decoding the 'Cautious Buy' on Furmonertinib

The High-Stakes Gamble: Summit's Vision vs. Akeso's Strategic Play with Ivonesimab

A Grand Promise, A Tricky Map: Navigating Cancer with Antibody-Drug Conjugates

A Shifting Tide: The Revolution in Lung Cancer Care

Breakthrough in Lung Cancer Treatment: Positive Phase 3 OPTITROP-Lung04 Trial Results for Sacituzumab Tirumotecan Unveiled

Cullinan Therapeutics' Breakthrough Cancer Drug Shows Remarkable Efficacy Against Brain Metastases in Lung Cancer Patients

A New Dawn in Lung Cancer Treatment: Gilead and Arcus's Investigational Therapy Shows Promising Survival Advantage

Nuvation Bio Soars: Pioneering Trial Success Ignites "Buy" Rating from Jefferies

Summit Therapeutics' Lung Cancer Hope Faces Fierce Competition and Scrutiny

Summit Therapeutics Soars: Cancer Drug Ivonesimab Delivers Breakthrough Survival Gains, Igniting Retail Investor Frenzy

A New Horizon in Lung Cancer Treatment: FDA Grants Breakthrough Status to Lilly-Merck Combination Therapy

Groundbreaking Cancer Drug Ivonescimab Propels Akeso Shares After Major Clinical Trial Success